We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
PURPOSE Severe ( grade > or= 3 ) pulmonary hemorrhage ( PH ) in advanced non-small-cell lung cancer was observed in two prospect i ve , r and omized , phase II ( N = 99 ) and phase III ( N = 878 ) trials of bevacizumab plus carboplatin and paclitaxel . Retrospective case-control and cohort analyses were conducted to identify associated radiographic and clinical risk factors for PH . PATIENTS AND METHODS Six patients with PH from the phase II trial , 15 potential PH patients with hemorrhage at any site from the phase III trial , and their matched controls were evaluated with review of baseline and on-treatment radiographs by an independent radiology facility , blinded to patient/control status . Patients with severe ( grade > or= 3 ) PH from each trial were matched with up to three controls based on sex , age group , histology ( phase II ) , or sex and age group ( phase III ) . RESULTS Seven PH patients in the phase III trial were identified as severe PH . Six of the patients were early onset ( occurred < 150 days of initiating bevacizumab ) and one was late onset . Baseline tumor cavitation , not tumor location , was identified as the only potential risk factor for patients with early onset . Combined analysis of severe PH patients from the phase II and phase III trials ( n = 13 ) , compared with their pooled matched controls ( n = 42 ) , did not identify any additional baseline radiographic or clinical variables associated with PH . CONCLUSION PH was an uncommon event . Based on these analyses , baseline tumor cavitation may be a potential risk factor for PH . No other baseline clinical variables were predictive for PH although the number of events was small
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV